Not for distribution to U.S. news wire services or dissemination in the
Ticker: TSX - TOS
Shares Outstanding: 72,888,182
QUÉBEC CITY, March 4, 2013 /CNW Telbec/ - TSO3 Inc. ("TSO3" or the "Company") (TSX: TOS) an innovator in sterilization technology
for medical devices in healthcare settings, is pleased to announce
today that it has successfully completed its previously announced
public offering of 7,000,000 common shares (the "Common Shares"). The
offering was completed on a bought deal basis through a syndicate of
underwriters co-led by Desjardins Securities Inc. and Canaccord Genuity
Corp. and including Byron Capital Markets Ltd. and Laurentian Bank
Securities Inc., at a price of $1.00 per Common Share for aggregate
gross proceeds to TSO3 of $7,000,000 (the "Offering").
The Common Shares were offered through a short-form prospectus filed in
all provinces of Canada. The Common Shares being issued in the offering
have been approved for listing on the Toronto Stock Exchange. Following
the issuance of the shares, there are 72,888,182 Common Shares of TSO3 issued and outstanding.
Net proceeds from the Offering will be used to accelerate new product
development, strengthen the Company's financial position enabling the
Company to continue to actively pursues US regulatory clearance for the
STERIZONE® 125L+ Sterilizer, and negotiate an appropriate channel
"We are pleased to consolidate our financial position, enabling the
Company to continue to move forward on multiple fronts, creating
additional value for our shareholders", said R.M. (Ric) Rumble, CEO of
TSO3. "The following months and quarters are expected to see significant
progress. This infusion of capital allows us to fund each of our
previously communicated projects."
This news release is not an offer of securities for sale in the United
States and is not an offer to sell or solicitation of an offer to buy
any securities of the Company, nor shall it form the basis of, or be
relied upon in connection with any contract for purchase or
subscription. Securities may not be offered or sold in the United
States absent registration under the U.S. Securities Act of 1933 (the "Securities Act") or an exemption from registration thereunder.
These securities have not been and will not be registered under the
Securities Act or the securities laws of any state and may not be
offered or sold in the United States absent registration under the
Securities Act and applicable state securities laws or pursuant to an
applicable exemption therefrom.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solutions to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts (including, without
limitation, those regarding the timing or outcome of any financing
undertaken by TSO3) are forward-looking statements that involve certain risks,
uncertainties and hypotheses, including, but not limited to, general
business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other risks and
SOURCE: TSO3 Inc.
For further information:
Director - Investor and Business Relations
(418) 651-0003, Ext. 237